Investigators from the Florida campus of the Scripps Research Institute have found that a compound that favors a certain biological pathway could provide scientists with a roadmap for future development of more effective drugs for addiction. In both cell and animal studies, researchers discovered that the compound, known as 6'-guanidinonaltrindole (6'-GNTI), has a strong disposition toward a single biological pathway--the kappa opioid receptor. Story